This novel enhancer is easily integrated into existing workflows, and it produces 2-4x higher titers across a range of serotypes, cellular growth media formulations, and transfection platforms. RevIT™ AAV Enhancer can further drive down upstream manufacturing costs by permitting the use of lower levels of plasmid DNA while maintaining high-quality titers. Continual improvements in both upstream and downstream AAV manufacturing processes will allow the next generation of gene therapies to reach a broader audience.
